Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating

Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.

Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating

Stocks chart

On November 18, LifeSci Capital reiterated a Buy rating on Tectonic Therapeutic, Inc. stock with a price target of $88. Tectonic Therapeutic, Inc. is a biotechnology company that focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors.

Tectonic Therapeutic, Inc. develops the GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. One of the lead product candidates of the firm is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia, a GPCR modulator bispecific for treating fibrosis, and other GPCR modulators.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term